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Across the US, 30%, or approximately one third of people meet the criteria for at 
least one mental illness.1 Of those with severe mental illness (SMI), namely schizophrenia 
and bipolar disorder, the mortality rate is more than twofold compared to the general 
population.2 The cardiovascular risk factors that contribute to cardiovascular related 
deaths, including metabolic disease and type II diabetes, are not only modifiable, but 
staggeringly higher for those with SMI.3 Though antipsychotic drug prescription is the 
standard protocol for SMI treatment, such drug effects on cardiovascular risk factors 
and related deaths exacerbate the much higher mortality rate for the severely mentally 
ill population. Due to both the prevalence of SMI and the physical comorbidities that it 
entails, analysis of healthcare costs associated with this population are an essential part 
of general health and policy improvement for the U.S. Therefore, a breakdown of the 
healthcare costs of this population requires not only acknowledgment of the modes of 
treatment for mental illness specifically, but also the identification and cost-analysis of 
the commonly associated physical comorbidities. This is especially important 
considering SMI is almost always considered chronic, and many SMI patients qualify for 
either Medicare, Medicaid, or both. Certain gaps in coverage can lead to lack of 
preventive care, exacerbating the cost burden.4  
From a clinician’s perspective, assessing relevant scientific studies and reviews to 
change the relationship between primary care and psychiatry is necessary to dampen 
the high mortality rate of the SMI population.  
From a policy-maker’s perspective, analyzing the cause and effect balance 
between managing costs of care directed at the SMI itself against the adjunct costs 
from physical comorbidity calls for a change in the structure of therapeutic care and 
how the SMI population accesses primary care.  
The Collaborative Care model is a health care model that unifies psychiatric, 
behavioral, and primary care to support the mental, behavioral, and physical health of 
patients. By supporting holistic healthcare, the high cost of care for the SMI population 
will be diminished. The model includes four parts: patient-centered care, population-
based care, measurement-based treatment to target, and evidence-based care. 
Swapping oral antipsychotics with injectable versions will be especially cost-effective by 
improving adherence rates, and thus, reducing institutionalization and other 
hospitalizations. By enforcing the Collaborative Care model through community health 
center interventions, clinicians and policy makers will be able to work together to 
effectively leverage the health of the SMI population while eroding the high health 
care expenditure that this population currently imposes on states.   
 
                                                            
1 Marth Ward and Ann Schwartz, "Challenges in Pharmacologic Management of the Hospitalized Patient with Psychiatric Comorbidity," Journal of 
Hospital Medicine 8, no. 9 (2013): 523, 
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=her&AN=90096361&site=ehost-live. 
2 Kai G. Kahl, Mechthild Westhoff-Bleck, and Tillmann H. C. Krüger, "Effects of Psychopharmacological Treatment with Antidepressants on the 
Vascular System," Vascular Pharmacology 96, (2017): 11, 
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=a9h&AN=125141989&site=ehost-live. 
3 John W. Newcomer, "Comparing the Safety and Efficacy of Atypical Antipsychotics in Psychiatric Patients with Comorbid Medical Illnesses," The 
Journal of Clinical Psychiatry 70 Suppl 3 (2009): 30-31, http://search 
.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=cmedm&AN=19570499&site=ehost-live.  
4 Linda Simoni-Wastila, Ilene H. Zuckerman, Thomas Shaffer, Christopher M. Blanchette, and Bruce Stuart, "Drug use Patterns in Severely Mentally Ill 
Medicare Beneficiaries: Impact of Discontinuities in Drug Coverage," Health Services Research 43, no. 2 (2008): 504, 
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=her&AN=31424857&site=ehost-live. 
Introduction  
Antipsychotic Drug Use: Managing Cardiometabolic and Cost Effects 
 
2 
2 Braga 
 
What is SMI? 
Severe mental illness, or SMI, represents a select group of diagnoses in the 
mentally ill population. These SMIs have similarities in their presentation and are 
oftentimes treated with the same types of psychotropic drugs. Researchers consistently 
use the label SMI to refer to mental illnesses characterized by psychosis or related 
episodes; episodes of psychosis are indicative of a break from reality, often in the form 
of hallucinations or delusions. The two diagnoses that most commonly encompass SMI 
are schizophrenia and bipolar disorder.5 
 
Higher Morbidity through Physical Illness 
Morbidity refers to the presence of disease. Multiple clinical studies across various 
countries have established that those with SMI suffer significantly greater morbidity than 
the general population.6 While some may assume that the leading cause of death for 
SMI patients is from the mental illness itself, physical impairments are at the forefront, 
leading to acute cardiovascular events such as heart attack and stroke.7 In fact, for the 
mentally ill population as a whole, cardiovascular disease is the leading cause of death 
across the United States.8   
 
Higher Mortality Due to Drug Use 
A mortality rate refers to the rate of death among a population. Countless 
studies and reviews illustrate that SMI sufferers exhibit a notably higher mortality rate as 
compared to the general population; one 2009 study found that SMI patients in public 
hospitals and mental centers lose about 25 to 30 years of potential life,9 while another 
review estimated that they die, on average, 15 to 20 years earlier than those without 
SMI.10 
Additionally, sudden cardiac death rate doubles among users of first-generation 
antipsychotics, such as haloperidol, and users of second-generation antipsychotics, like 
quetiapine.11 Virtually all patients that present with SMI take oral antipsychotics, 
especially the more modern second-generation antipsychotics, either continuously or 
at some point in life due to their efficacy and tolerability.12 Multiple studies have 
established this conspicuously increased risk of cardiovascular death, and the gap is 
ever widening.13 In fact, approximately 60% of the premature mortality among SMI 
patients is due to physical illness alone, particular causes being coronary heart disease, 
atherosclerosis, hypertension, and stroke, which are all metabolically related.14 Not 
including suicide, other leading causes of death include respiratory diseases, diabetes, 
and cancer.15  
 
What are antipsychotics?  
Antipsychotics are typically psychiatrists' first choice for treating mental illnesses 
that deal with psychosis or related episodes, particularly schizophrenia and bipolar 
                                                            
5 Kahl, Westhoff-Bleck, and Krüger, "Effects of Psychopharmacological Treatment with Antidepressants on the Vascular System," 11.  
6 Ward and Schwartz, "Challenges in Pharmacologic Management of the Hospitalized Patient with Psychiatric Comorbidity," 523.  
7 Ibid. 
8 Newcomer, "Comparing the Safety and Efficacy of Atypical Antipsychotics in Psychiatric Patients with Comorbid Medical Illnesses," 30.  
9 Ibid.  
10 Kahl, Westhoff-Bleck, and Krüger, "Effects of Psychopharmacological Treatment with Antidepressants on the Vascular System," 11.  
11 Ward and Schwartz, "Challenges in Pharmacologic Management of the Hospitalized Patient with Psychiatric Comorbidity," 527.  
12 Newcomer, "Comparing the Safety and Efficacy of Atypical Antipsychotics in Psychiatric Patients with Comorbid Medical Illnesses," 32-33. 
13 Ward and Schwartz, "Challenges in Pharmacologic Management of the Hospitalized Patient with Psychiatric Comorbidity," 527.  
14 Kahl, Westhoff-Bleck, and Krüger, "Effects of Psychopharmacological Treatment with Antidepressants on the Vascular System," 11.  
15 Kahl, Westhoff-Bleck, and Krüger, "Effects of Psychopharmacological Treatment with Antidepressants on the Vascular System," 11.  
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disorder.16 Essentially, antipsychotics work to terminate and prevent psychosis and 
related episodes, such as bipolar mania.17 The beginning of first-generation 
antipsychotics, otherwise known as typical antipsychotics, dates back to the 1950s. The 
more commonly used second-generation antipsychotics, also called atypical 
antipsychotics, achieved FDA approval in the 1990s.18  Due to the ability of 
antipsychotics to subdue episodes of mental illness to a homeostatic level, they are an 
essential part of the psychiatrist's toolkit, and an essential part of the therapeutic 
regimen for SMI. And, like all drugs on the market, antipsychotics have the potential to 
cause adverse side effects. What differentiates antipsychotics from other drugs, 
however, is the great capacity of cardiovascular risk that comes along with them. In a 
2012 review of studies targeting adverse side effects, second-generation antipsychotics 
were found to frequently cause weight gain, insulin resistance, dyslipidemia (high 
cholesterol), type II diabetes, and hypertension. What's more is that they did so much 
more significantly than first-generation antipsychotics.19 As Newcomer points out in a 
2009 paper on safety and efficacy of atypical antipsychotics, "Individual antipsychotic 
medications are associated with different levels of risk for adverse effects on body 
weight and body fat […] In general, as adiposity increases, so does risk for dyslipidemia, 
hypertension, and hyperglycemia, conditions that all contribute to the risk of 
[cardiovascular disease]."20 In other words, although antipsychotics in the general sense 
are more than likely to cause an increase in body fat, which subsequently leads to 
serious cardiovascular risk factors, certain individual antipsychotics pose a much 
greater risk than others. Ziprasidone, fluphenazine, and haloperidol are three examples 
of antipsychotics associated with relatively low risk of weight gain.21 Conversely, 
researchers attribute significant weight increases to the more commonly used second-
generation antipsychotics clozapine and olanzapine. Unfortunately, these two are also 
the ones that seem to offer the greatest therapeutic effect. Clozapine, though linked 
with the most weight gain as compared to other antipsychotics, has been termed the 
'gold standard treatment' for patients with treatment-resistant schizophrenia, as its 
antipsychotic effects are statistically paramount to the effects of other antipsychotics 
on treatment resistant types.22  
It seems as if the key problem in the modern psychiatric school of thought lies in 
the guideline of Western medicine: identify the source of illness and treat it with drugs. 
This is exactly the function that antipsychotics play in those with SMI – they subdue 
acute psychotic or manic episodes and can also prevent them. It is the logical 
framework of psychiatric therapy, and exactly why psychiatrists prefer to prescribe 
clozapine and the like. However, with such a therapeutic framework, comorbidities 
arise. Instead of holistically approaching therapeutics by taking a patient's physical risk 
factors into account, the standard American psychiatrist targets isolated mental 
disorders and treats them respectively. Unfortunately, this does not mimic the 
interrelated systems of the body, which affect one another.23  
 
                                                            
16 Siegfried Kasper, "The Metabolic Syndrome and Antipsychotic Treatment," Annals of General Psychiatry 7, (2008): 1, 
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=a9h&AN=35703860&site=ehost-live. 
17 Newcomer, "Comparing the Safety and Efficacy of Atypical Antipsychotics in Psychiatric Patients with Comorbid Medical Illnesses," 32.  
18 "A History of Atypical Antipsychotics," USA Today (May 2, 2006): 5a, 
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=a9h&AN=J0E075503181706&site=ehost-live. 
19 Pavo Filaković, Anamarija Petek Erić, and Ljiljana Radanović-Grgurić, "Metabolic Syndrome and Psychotropic Medications," Medicinski Glasnik 9, 
no. 2 (2012): 181, http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=a9h&AN=79820876&site=ehost-live. 
20 Newcomer, "Comparing the Safety and Efficacy of Atypical Antipsychotics in Psychiatric Patients with Comorbid Medical Illnesses," 32.  
21 Ibid., 33.  
22 Ibid.  
23 Shiv Gautam, "Fourth Revolution in Psychiatry - Addressing Comorbidity with Chronic Physical Disorders," Indian Journal of Psychiatry 52, no. 3 (Jul, 
2010): 213, http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=a9h&AN=54556866&site=ehost- live.  
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Case Study: Obesity and Antipsychotic Use 
In a 2012 study of body mass index and obesity of SMI patients, being overweight 
or obese was statistically very common in the sample. Additionally, "prescription of 
antipsychotics was associated with obesity and the total percentage dose of 
antipsychotic correlated with BMI."24 Essentially, this finding supports the notion that, 
assuming those prescribed with antipsychotics are indeed taking them, not only are the 
drugs themselves correlated with BMI, but the correlation is dose dependent. In this 
particular case, the higher the dose of antipsychotics, the higher the patient's BMI.  
But what about causation? Was it the antipsychotic medications themselves that 
caused the greater BMI of the sample, or were there more factors at play that directly 
affected BMI? For this study and many others, the answer remains unclear. What the 
results seem to show, however, is the presence of factors, other than psychotropic 
medications, at play. The 2012 study mentioned, "antipsychotic medication, poor diet, 
and a lack of motivation to exercise," were important contributory factors to the high 
prevalence of overweight and obese subjects.25 Moreover, the mental health 
community saw mortality from all causes in schizophrenic patients double between the 
1970s and the 1990s, key decades for antipsychotic introduction.26  
 
What is metabolic syndrome? 
Metabolic syndrome is a clustered diagnosis that encompasses obesity, 
hypertension, impaired glucose-tolerance, and dyslipidemia. Due to its constituents, 
metabolic syndrome is a risk factor for type II diabetes, cardiovascular disease, and 
cardiovascular related death. The incidence for metabolic syndrome increases with 
increase in adiposity, meaning that overweight or obese patients are especially at risk.27 
 
How do antipsychotics cause metabolic syndrome? 
Psychotropic drugs as a whole may influence weight gain, "through increased 
food consumption and disruption of satiety signaling system."28 Many times, weight gain 
is directly caused by second-generation antipsychotics. They can cause fat distribution 
to concentrate around the abdomen, which, in turn, is a direct cause for insulin 
resistance, the hallmark of type II diabetes. Since type II diabetes is a well-established 
risk factor for cardiovascular disease and cardiovascular related death, what is 
illustrated with antipsychotic drug use is a train of cause and effect with a sour final 
destination. In fact, the correlations between antipsychotics, metabolic disease, and 
diabetes are so distinct that the FDA (Federal Food and Drug Administration) asked the 
producers of second-generation antipsychotics to include a warning on the label of 
their products. This warning specifies the need for blood sugar tests before treatment 
and in regular intervals throughout. The American Diabetes Association has similarly 
published a consensus outlining the higher risks for obesity, type II diabetes, and 
dyslipidemia associated with some antipsychotics. The Association found the 
antipsychotics with the highest risk to be clozapine and olanzapine, while those with the 
                                                            
24 C. Haw and S. Bailey, "Body Mass Index and Obesity in Adolescents in a Psychiatric Medium Secure Service," Journal of Human Nutrition and 
Dietetics: The Official Journal of the British Dietetic Association 25, no. 2 (2012): 167, 
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db= cmedm&AN=21585567&site=ehost-live.  
25 Ibid.  
26 Ibid.  
27 Kasper, "The Metabolic Syndrome and Antipsychotic Treatment," 1. 
28 Filaković, Erić, and Radanović-Grgurić, "Metabolic Syndrome and Psychotropic Medications," 180.   
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lowest risk are ziprasidone and aripriprazole.29 In one study of 95 severely mentally ill 
patients, 100% of patients on a clozapine regimen were overweight or obese, and 
approximately 90% of the patients on an olanzapine regimen had a raised BMI. The 
study concluded that clozapine and olanzapine both have the inclination to cause 
meaningful weight gain in a dose-dependent manner.30 As aforementioned, clozapine 
is coincidentally the antipsychotic considered to be the 'gold standard' treatment for 
hard-to-treat types,31 and since this is often the case for those with SMI, the prescription 
of clozapine may be a critical factor in the mortality rate of the SMI population. A 
particular marker from another study shows that the weight gain resultant from 
antipsychotic use increases exponentially from the start of treatment and does not 
reach plateau until several weeks or months from the onset, supporting the causation 
argument.32 Furthermore, according to Haw and Bailey, the extra weight gained is not 
prone to come off: "at least 70% of obese adolescents will remain obese as adults,"33 
and the mere presence of obesity in adolescence can cause serious physical 
comorbidities like diabetes, cardiovascular disease, and cancer. This sequence forges 
the direct link between adolescent obesity and increased mortality in adulthood.34  
Antipsychotics can directly cause weight gain by interfering with signals in the 
brain that tell the body the stomach is full, more than likely leading to overeating. 
Additionally, antipsychotics can directly reduce the intensity of physical activity by the 
same mechanism.35 One such hormone that plays a role in appetite is leptin. Treatment 
with antipsychotics of high metabolic risk, such as clozapine and olanzapine, can 
cause a drug-induced resistance to leptin, which indicates satiation to the brain. This 
phenomenon explains the event that circulating leptin levels double at the onset of 
treatment with both clozapine and olanzapine, suggesting that the body is not using 
the leptin in the bloodstream to signal the brain – a drug-induced leptin resistance. 
Some researchers hypothesize that since leptin and insulin are "mutually coupled in this 
system,"36 it is possible that the antipsychotics themselves affect insulin in the same way, 
making insulin resistance potentially independent of weight gain for some patients.37 
Other scientific reviews claim that this hypothesis is indeed accepted fact, as insulin 
dysfunction in those taking clozapine and olanzapine has occurred in patients of a 
healthy weight, healthy clinical trial volunteers, and animal models.38 
 
How do antipsychotics increase the risk of diabetes? 
Two risk factors for diabetes, dyslipidemia and increased insulin resistance, have 
the potential to be direct effects of some psychotropic drugs; antipsychotics can cause 
insulin resistance even without weight gain as the causal factor.39  
The role of insulin is the distinctive feature in type II diabetes. The body secretes 
insulin to regulate blood sugar level, which is usually raised during digestion. An 
absence of insulin allows blood sugar levels to spike, while insulin secretion lowers blood 
sugar levels by storing the sugar in the liver or as body fat. The hormone can also 
                                                            
29 Ibid., 180-184. 
30 Haw and Bailey, "Body Mass Index and Obesity in Adolescents in a Psychiatric Medium Secure Service," 169-170.  
31 Newcomer, "Comparing the Safety and Efficacy of Atypical Antipsychotics in Psychiatric Patients with Comorbid Medical Illnesses," 33.  
32 Filaković, Erić, and Radanović-Grgurić, "Metabolic Syndrome and Psychotropic Medications," 181.   
33 Haw and Bailey, "Body Mass Index and Obesity in Adolescents in a Psychiatric Medium Secure Service," 169-170.  
34 Ibid., 169.  
35 Filaković, Erić, and Radanović-Grgurić, "Metabolic Syndrome and Psychotropic Medications," 184.   
36 Ibid.   
37 Ibid. 
38 Katrina Weston-Green, Xu-Feng Huang, and Chao Deng, "Second Generation Antipsychotic-Induced Type 2 Diabetes: A Role for the Muscarinic 
M3 Receptor," CNS Drugs 27, no. 12 (2013): 1071, 
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=cmedm&AN=24114586&site=ehost-live. 
39 Filaković, Erić, and Radanović-Grgurić, "Metabolic Syndrome and Psychotropic Medications," 180-184.    
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reduce food intake by interacting with insulin receptors in various parts of the brain, 
reducing the urge to eat.40 
Because drugs like clozapine and olanzapine can increase the peripheral 
resistance to insulin, these and antipsychotics like these can directly cause diabetes. 41 
Peripheral resistance to insulin refers to the decreased ability or complete inability of 
peripheral tissues, meaning muscle and fat, to absorb sugar from the blood.42  
One specific hormone receptor that some antipsychotics react with, termed 
'M3R,' has been identified as, "a predictor of antipsychotic diabetogenic liability."43 M3R 
also has a relationship with weight gain. Accumulated results from several studies show 
that acetylcholine muscarinic receptors – M3R, for example – play important roles in the 
pathology of SMI and antipsychotic drug efficacy. The affinity of metabolically high risk 
second-generation antipsychotics (e.g., clozapine and olanzapine) to bind to M3R 
receptor sites is high, while second-generation antipsychotics that exhibit low M3R 
binding affinity (e.g., risperidone, ziprasidone, aripiprazole) have much lower adverse 
metabolic effects. This trend reflects the high M3R binding affinity of a first-generation 
antipsychotic called chlorpromazine, a foreshadowing of the drug's 'diabetogenic 
effect.'44 
 
Stop the flow of antipsychotics?  
From a clinical standpoint, it is fair to say that SMI sufferers need their 
medications, especially following prior psychotropic drug treatment. Sudden cessation 
of psychotropic drugs can lead to mild or even life-threatening nervous system 
complications and/or psychiatric decompensation.45 For example, in a study of 
pregnant women who abruptly stopped their psychotropic drug therapy, as is the 
standard protocol during pregnancy, nearly one third of the sample population 
experienced suicidal ideation, one of the primary factors that psychotropic drugs aim 
to prevent.46 Movement disorders resembling parkinsonism, distinguished by tremors, 
and dyskinesias, which impair voluntary movement, may even occur upon cessation.47 
With these risks in mind, vacating antipsychotic treatment completely is not the solution 
to the mortality gap from a clinical standpoint.  
 
Cost implications of SMI treatment  
Due to the complexity and largely unknown pathology of SMIs like schizophrenia 
and bipolar disorder, treatment costs among the population are burdensome to the 
U.S. healthcare system. From a policy perspective, this poses an economic problem 
that suggests reform, especially since mental health care in general accounts for about 
10% of U.S. Medicaid costs; as of 2013, schizophrenia alone cost Medicaid and other 
state agencies $21.4 billion.48 Physical comorbidities among SMI sufferers are also 
correlated with a substantial increase in economic burden for states. Schizophrenia 
patients alone constitute about 10% of the permanently disabled and are therefore 
                                                            
40 Weston-Green, Huang, and Deng, "Second Generation Antipsychotic-Induced Type 2 Diabetes: A Role for the Muscarinic M3 Receptor," 1071.  
41 Filaković, Erić, and Radanović-Grgurić, "Metabolic Syndrome and Psychotropic Medications," 184.   
42 Ibid. 
43 Weston-Green, Huang, and Deng, "Second Generation Antipsychotic-Induced Type 2 Diabetes: A Role for the Muscarinic M3 Receptor," 1072.  
44 Ibid. 
45 Ward, Martha and Ann Schwartz, "Challenges in Pharmacologic Management of the Hospitalized Patient with Psychiatric Comorbidity," Journal of 
Hospital Medicine 8, no. 9 (2013): 528, 
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=her&AN=90096361&site=ehost-live. 
46 Ibid., 524 
47 Ward and Schwartz, "Challenges in Pharmacologic Management of the Hospitalized Patient with Psychiatric Comorbidity," 525.  
48 Zachary S. Predmore, Soeren Mattke, and Marcela Horvitz-Lennon, "Improving Antipsychotic Adherence among Patients with Schizophrenia:  
Savings for States," Psychiatric Services (Washington, D.C.) 66, no. 4 (2015): 343,  
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=cmedm&AN=25555222&site=ehost-live. 
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dependent on sources of public assistance.49 Not only does physical comorbidity 
compound the treatment costs of SMI patients through adverse cardiovascular events 
that often lead to costly hospitalizations or tertiary care – it also increases the likelihood 
that these individuals will be absent in the labor force and unable to help provide for 
family members such as their children.50 Withdrawal from these areas of economic 
contribution often leads to an even greater cost for the state to financially provide for 
SMI sufferers and their families.  
In order to troubleshoot for healthcare cost issues, it is necessary to review cost 
analyses and specify expensive components of care for this population. Having SMI, 
and being actively treated for it, has been found to increase the risk of obesity, 
cardiovascular disease, and diabetes. Another factor that compounds the cost 
problem is the finding that while the addressed physical comorbidities are more 
prevalent in the SMI population, patients are less likely to report them and clinicians are 
less likely to treat them, posing a primary care discrepancy.51 In particular, screening 
rates for obesity and weight-related metabolic disorders is low.52 When cardiometabolic 
conditions such as hypertension are left untreated, adverse events that require costly 
hospitalizations are more likely to occur. In another cohort study of 67,862 bipolar 
sufferers in a managed care population, patients taking second-generation 
antipsychotics alone had an estimated 24% higher cost than the general population, 
while those taking both mood stabilizers and second-generation antipsychotics, which 
is the most prominent case for bipolar sufferers, posed an estimated 52% higher 
healthcare cost. For bipolar sufferers, the key cost components included inpatient care 
(31%), outpatient visits (16%), prescription drugs (24%), and physician encounters (16%). 
However, though prescription drug costs and doctor visits were among the most 
expensive cost components, merely 33% of total treatment costs were specific to 
bipolar disorder. Instead, the remaining 67% of the costly healthcare provided to 
bipolar sufferers was allocated for the treatment of comorbidities. To boot, each 
comorbidity identified individually had a noteworthy impact on cost: there was not an 
outlier skewing the data.53 Similarly, cost components for the treatment of schizophrenia 
comprise much more than the direct costs of inpatient psychiatric care and related 
pharmacotherapy. Although patients diagnosed with schizophrenia make up only 1% 
of the population, costs to treat them accumulate to 2.5% of the U.S. health care 
expenditure.54 The annual treatment cost of schizophrenia is similar to the cost of 
treating coronary artery disease across the whole population.55 Based on these results 
and results of various studies on the cost breakdown of healthcare for those with SMI, 
efforts to control cost must logically target the comorbidities that arise in concurrence 
with SMI as well as the use of other avenues that can limit hospitalizations.  
 
 
Implementing Collaborative Care to Manage Costs  
 
                                                            
49 M. Seshamani, "Is Clozapine Cost-Effective? : Unanswered Issues," European Journal of Health Economics 3, (2002):  
104, http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=her&AN=15205453&site=ehost-live. 
50 A-La Park, David McDaid, Prisca Weiser, Carolin Von Gottberg, Thomas Becker, and Reinhold Kilian, "Examining the Cost Effectiveness of  
Interventions to Promote the Physical Health of People with Mental Health Problems: A Systematic Review," BMC Public Health 13, no. 1 (2013): 2,  
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=her&AN=90248116&site=ehost-live. 
51 Ibid., 1. 
52 Ibid. 
53 Jeff J. Guo, Jr Keck Paul E., Hong Li, Raymond Jang, and Christina M. L. Kelton, "Treatment Costs and Health Care Utilization for Patients with Bipolar 
Disorder in a Large Managed Care Population," Value in Health 11, no. 3 (May, 2008): 419-421, 
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=her&AN=32073797&site=ehost-live.  
54 Seshamani, "Is Clozapine Cost-Effective? : Unanswered Issues," 104-106.  
55 Ibid.  
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The increased cardiovascular risk factors and related adverse events among SMI 
patients relative to the general population is acknowledged by health care providers 
and researchers. Additionally, policy makers have identified the costly public 
consequence. Both primary care physicians and psychiatrists face obstacles in the 
treatment of the SMI population. While general practitioners lack a deep knowledge 
about the psychiatric features and treatment options for SMI sufferers, psychiatrists lack 
insight and expertise in managing physical comorbidities that are commonly linked with 
SMI treatment.56 To combat the problem, policy makers and researchers worldwide 
have teamed up in hopes of finding a resolution. In an important Cochrane review, the 
Collaborative Care model demonstrated clinical efficacy as well as cost-effectiveness 
in over 80 randomized controlled trials.57  
Collaborative Care is an evidence-based model of care that integrates the 
mental and behavioral health aspects of psychiatry with the primary care setting. In the 
Collaborative Care health care model, clinicians with concentrations in mental, 
behavioral, and primary care are team members and take a team-based approach to 
treating the SMI patient. To implement the collaborative care model, the care team 
must adhere to four principles: patient-centered team care, population-based care, 
measurement-based treatment to target, and evidence-based care.58  
 
59 
 
 
                                                            
56 Anne Looijmans, Frederike Jörg, Richard Bruggeman, Robert Schoevers, and Eva Corpeleijn, "Design of the Lifestyle Interventions for Severe  
Mentally Ill Outpatients in the Netherlands (LION) Trial; a Cluster Randomised Controlled Study of a Multidimensional Web Tool Intervention to Improve  
Cardiometabolic Health in Patients with Severe Mental Illness," BMC Psychiatry 17, (2017): 2,  
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=afh&AN=122365452&site=ehost-live. 
57 Christina Mangurian, Grace C. Niu, Dean Schillinger, John W. Newcomer, James Dilley, and Margaret A. Handley, "Utilization of the Behavior  
Change Wheel Framework to Develop a Model to Improve Cardiometabolic Screening for People with Severe Mental Illness," Implementation  
Science: IS 12, no. 1 (2017): 2,  
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=cmedm&AN=29137666&site=ehostlive. 
58 Ibid.  
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Patient-Centered Team Care  
  
Lifestyle interventions  
 
Lifestyle interventions in the SMI population are critical, as these patients are less 
likely to access primary care than the general population.60 Particular lifestyle behaviors 
that are negatively affected by incidence of SMI are lower levels of autonomous 
motivation towards physical activity, unhealthy diet, non-adherence to medication 
regimens, poor hygiene, and inadequate maintenance of physical health conditions.61 
Given the troublesome high level of metabolic disease and associated risk for 
premature death in those with SMI, implementation of lifestyle interventions to tackle 
the diet, exercise, hygiene, and maintenance of physical disease are of utmost 
importance.62   
In a UK study in which researchers interviewed SMI patients as part of a lifestyle 
intervention program, there seemed to be a preliminary belief among patients that 
they were healthy and did not need to immediately confront the risk factors that they 
possessed. For instance, one interviewee stated that since their doctor performs a 
yearly blood test review, he or she did not need additional attention paid to risk  
factors.63 When asked if smoking cessation may prevent further stroke, another patient 
stated, “No – I don’t really think it does – no.”64 Similarly, another interviewee failed to 
understand the link between dietary salt intake and high blood pressure. These 
examples demonstrate the lack of general health knowledge and lack of urgency to 
change that clinicians need to address among the population via lifestyle interventions. 
Additionally, participation in a lifestyle intervention is maximized when the initial 
approach is made by each patient’s caseworker. Another UK editorial poses that when 
patients are admitted to the hospital, mental health services should use the time frame 
as a window to recommend and explain participation in a lifestyle intervention.65  
In a Dutch study of SMI patients, lifestyle interventions were shown to be effective 
for both weight loss and reduction in cardiometabolic risk factors like high blood sugar 
and cholesterol levels.66 In the Dutch model, the three key components of lifestyle 
interventions include exercise, diet, and behavior. Appointments per patient should be 
made on a weekly or nightly basis for up to six months with a nurse in a primary care or 
community health setting.67 Psychiatric nurses and therapists use behavioral therapy 
strategies to improve self-management skills such as goal setting and creation of action 
                                                            
60 Robert Pearsall, Susan Hughes, John Geddes, and Anthony Pelosi, "Understanding the Problems Developing a Healthy Living Programme in Patients  
with Serious Mental Illness: A Qualitative Study," BMC Psychiatry 14, no. 1 (2014): 3,  
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=a9h&AN=94426984&site=ehost-live. 
61 Looijmans, Anne, Frederike Jörg, Richard Bruggeman, Robert Schoevers, and Eva Corpeleijn, "Design of the Lifestyle Interventions for Severe  
Mentally Ill Outpatients in the Netherlands (LION) Trial; a Cluster Randomised Controlled Study of a Multidimensional Web Tool Intervention to Improve  
Cardiometabolic Health in Patients with Severe Mental Illness," BMC Psychiatry 17, (2017): 2,  
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=afh&AN=122365452&site=ehost-live. 
62 Ibid., 10.  
63 Pearsall, Robert, Susan Hughes, John Geddes, and Anthony Pelosi, "Understanding the Problems Developing a Healthy Living Programme in  
Patients with Serious Mental Illness: A Qualitative Study," BMC Psychiatry 14, no. 1 (2014): 6,  
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=a9h&AN=94426984&site=ehost-live. 
64 Ibid., 8.  
65 Ibid., 8-13. 
66 Looijmans, Jörg, Bruggeman, Schoevers, and Corpeleijn, "Design of the Lifestyle Interventions for Severe Mentally Ill Outpatients in the Netherlands  
(LION) Trial; a Cluster Randomised Controlled Study of a Multidimensional Web Tool Intervention to Improve Cardiometabolic Health in Patients with  
Severe Mental Illness," 2. 
67 David Osborn, Alexandra Burton, Rachael Hunter, Louise Marston, Lou Atkins, Thomas Barnes, Ruth Blackburn, et al, "Clinical and Cost-Effectiveness  
of an Intervention for Reducing Cholesterol and Cardiovascular Risk for People with Severe Mental Illness in English Primary Care: A Cluster  
Randomised Controlled Trial," The Lancet.Psychiatry (2018): 147,  
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=cmedm&AN=29396118&site=ehost-live. 
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plans.68 Other behavioral measures should include physical activity and diet 
questionnaires, which the nurse or behavioral health manager should review.69  
The Dutch lifestyle intervention study used key steps to implement lifestyle 
interventions. The chart below describes the four most important steps in order. 
 
 
Lifestyle Intervention Steps70 
1. Identify unhealthy behaviors Behaviors highly related to health risks 
2. Create a lifestyle plan 
After discussion with the nurse, patient should set three 
attainable goals. The nurse’s role is to guide realistic goal 
setting. 
3. Evaluate lifestyle goals 
Evaluate goals regularly. During every regular care visit, 
patient and nurse should fill in a new questionnaire to 
measure progress. 
4. Indicate barriers and 
facilitators in achieving goals 
Nurse should guide patient in discussing what factors 
foster goal achievement and what factors inhibit goal 
achievement.  
 
 
While the nurse is present to offer guidance during the intervention, the patient 
should take leadership in creating a lifestyle plan and setting lifestyle goals. In this way, 
each individual patient will be able to tailor the lifestyle intervention to his or her specific 
recovery wishes.71  
In a similar lifestyle intervention study conducted in the UK, the primary outcome 
was reduction in cholesterol levels, and the intervention was associated with fewer 
hospital admissions.72 Another study on lifestyle interventions across multiple countries 
determined that supervised walking was highly cost effective in a 16-week randomized 
trial of a tailored exercise program.73  
 
 
 
 
 
 
 
 
 
 
                                                            
68 Looijmans, Jörg, Bruggeman, Schoevers, and Corpeleijn, "Design of the Lifestyle Interventions for Severe Mentally Ill Outpatients in the Netherlands  
(LION) Trial; a Cluster Randomised Controlled Study of a Multidimensional Web Tool Intervention to Improve Cardiometabolic Health in Patients with  
Severe Mental Illness," 2. 
69 Osborn, Burton, Hunter, Marston, Atkins, Barnes, Blackburn, et al, "Clinical and Cost-Effectiveness of an Intervention for Reducing Cholesterol and 
Cardiovascular Risk for People with Severe Mental Illness in English Primary Care: A Cluster Randomised Controlled Trial," 147.  
70 Looijmans, Jörg, Bruggeman, Schoevers, and Corpeleijn, "Design of the Lifestyle Interventions for Severe Mentally Ill Outpatients in the Netherlands  
(LION) Trial; a Cluster Randomised Controlled Study of a Multidimensional Web Tool Intervention to Improve Cardiometabolic Health in Patients with  
Severe Mental Illness," 8, table 3. 
71 Ibid., 10. 
72Osborn, Burton, Hunter, Marston, Atkins, Barnes, Blackburn, et al, "Clinical and Cost-Effectiveness of an Intervention for Reducing Cholesterol and 
Cardiovascular Risk for People with Severe Mental Illness in English Primary Care: A Cluster Randomised Controlled Trial," 147-150.  
73 Park, McDaid, Weiser, Gottberg, Becker, and Kilian, "Examining the Cost Effectiveness of Interventions to Promote the Physical Health of People  
with Mental Health Problems: A Systematic Review," 4-8. 
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What community 
health/psychiatry needs to 
change 
Implement lifestyle interventions 
Who should perform the 
behavior Nurses or other behavioral health managers 
When to perform the 
behavior When seeing patients that take antipsychotic drugs 
Where to perform the 
behavior At community mental health clinics or primary care offices 
How often to perform the 
behavior Annually per patient 
For whom should they 
perform the behavior All patients taking antipsychotic drugs 
 
 
 
Population-based Care 
 
Invitations for Health checks 
 
It is commonly understood by the general population that physical health 
checks should occur at least once a year.74 A contributing factor to why SMI sufferers 
have higher levels of cardiovascular death may be due to the fact that they tend to 
volunteer symptoms less readily. For this reason, physical comorbidity in the early stages 
may go unidentified and unmaintained through the course of the morbidity.75 Evidence 
shows that invitations to pre-scheduled health checkups are an intervention method 
that is both time conducive and cost effective, and positively affects the rate at which 
SMI patients access primary care.76  
In an instrumental UK study evaluating SMI patient response to an invitation letter, 
70% of the SMI patients invited to a primary care-oriented health checkup attended. 
One important discrepancy of the study revealed that letters containing an open 
invitation produced a much lower attendance rate (37%) than the 70% attendance 
rate produced by invitation letters that indicated a specific date and time for the 
health check.77 Another UK study found that 68.3% of those who received invitation 
letters attended a health check,78 and yet another study provided that 63.3% of 
                                                            
74 Misuzu Fujita, Yasunori Sato, Kengo Nagashima, Sho Takahashi, and Akira Hata, "Impact of Geographic Accessibility on Utilization of the Annual  
Health Check-Ups by Income Level in Japan: A Multilevel Analysis," PLoS ONE 12, no. 5 (2017): 1-14,  
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=a9h&AN=122942297&site=ehost-live. 
75 Richard Gray and Sheila Hardy, "Is the use of an Invitation Letter Effective in Prompting Patients with Severe Mental Illness to Attend a Primary Care 
Physical Health Check?," Primary Health Care Research & Development (Cambridge University Press / UK) 13, no. 4 (2012): 347-348, 
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=a9h&AN=84125115&site=ehost-live. 
76 Ibid., 350-355. 
77 Ibid., 348.  
78 Alice S. Forster, Caroline Burgess, Lisa McDermott, Alison J. Wright, Hiten Dodhia, Mark Conner, Jane Miller, Caroline Rudisill, Victoria Cornelius, and  
Martin C. Gulliford, "Enhanced Invitation Methods to Increase Uptake of NHS Health Checks: Study Protocol for a Randomized Controlled  
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patients invited to a health check responded.79 Since age is not a factor that affects 
the respondent rate of health check invitation letters, SMI patients of all ages may 
benefit from this interventional method. Letters should not be sent to those in inpatient 
care, residential care, or prison, as these patients are rotationally seen by health care 
professionals. 80  
When patients were sent an invitation letter ten days before the pre-scheduled 
appointment, 70% attended.81 A short time period between the disposition of the letter 
by the office of the physician and acquisition of the letter by the patient is conducive to 
patient attendance because of the cognitive problems that often accompany SMI or 
are a side effect of a psychotropic medication regimen. One common problem is poor 
memory, and consequently, poor planning. If the patient does not attend the health 
check, the office should send out an invitation for another appointment. When offices 
send a secondary appointment, an additional 4% of patients attend the health check, 
reflecting about one sixth of absentees.82  
The widespread use of electronic medical records (EMR) by clinicians allows 
doctors to easily separate patients with SMI from patients without. This ability makes the 
invitation process an easy, quick, and inexpensive intervention method.  
 Evidence from related sources suggests that specific changes to health-check 
invitation letters can critically impact behavioral responses from patients.83 One UK 
study conducted in 2016 found that four critical changes to health-check invitation 
letters were particularly instrumental in improving patient attendance. The first was 
simplification; letters should be shortened to two, one-sentence paragraphs to reduce 
time and effort on behalf of the patient. The second change is the use of concrete 
statements and specified instructions. Thirdly, the heading of the letter should be 
emboldened and state that the intended patient is ‘due to attend’ a health check, 
rather than relaying that the patient is ‘invited to attend’ a health-check. The fourth 
change is the addition of a tear-off slip for the specified date and time of the 
appointment with an instruction for the patient to put the slip on their fridge or calendar 
as a reminder. These small, low cost changes to health check invitation letters were 
shown to improve patient attendance by 26% as compared to a standard health 
check invitation letter.84  
 
 
 
 
 
 
 
                                                            
Trial," Trials 15, no. 1 (2014): 2, 
http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=a9h&AN=110265355&site=ehost-live. 
79 Anna Sallis, Amanda Bunten, Annabelle Bonus, Andrew James, Tim Chadborn, and Daniel Berry, "The Effectiveness of an Enhanced Invitation Letter  
on Uptake of National Health Service Health Checks in Primary Care: A Pragmatic Quasi-Randomised Controlled Trial," BMC Family Practice 17,  
(2016): 2, http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=cmedm&AN=27009045&site=ehost-live. 
80 Gray and Hardy, "Is the use of an Invitation Letter Effective in Prompting Patients with Severe Mental Illness to Attend a Primary Care Physical Health 
Check?," 349-350.  
81 Ibid., 348. 
82 Ibid., 348-349.  
83 Sallis, Bunten, Bonus, James, Chadborn, and Berry, "The Effectiveness of an Enhanced Invitation Letter on Uptake of National Health Service Health  
Checks in Primary Care: A Pragmatic Quasi-Randomised Controlled Trial," 3. 
84 Ibid., 3-7.  
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What primary 
care/community health 
needs to change 
Send annual health check invitation letters, with specified 
day and time 
Who should perform the 
behavior Secretaries or office administration with help of EMR 
When to perform the 
behavior Ten days before the scheduled appointment 
Where to perform the 
behavior 
At administrative offices of community mental health 
clinics/primary care 
How often to perform the 
behavior 
Annually per patient (about 10-15 times per month given a 
typical community psychiatrist’s caseload) 
For whom should they 
perform the behavior All patients taking antipsychotic drugs 
 
 
Measurement-based Treatment to Target 
  
 Cardiometabolic screening  
 
Since cardiovascular and metabolic health is a target area for cost 
containment, cardiometabolic screening should be one of the most important 
measurement-based interventions for SMI patients. Traditionally, physicians screen 
patients for cardiovascular and metabolic risk factors at the primary care level. 
However, SMI patients are far less likely to utilize primary care than the general 
population.85 Instead, the care that SMI patients most commonly access originates from 
community mental health services like clinics.86 BMI, blood pressure, glucose and 
cholesterol monitoring are additionally recommended.87 In the UK, recommendations 
also include tests for liver function and prolactin levels even if symptoms are not 
present; prolactin testing is in line with UK bipolar disorder treatment guidelines, since 
certain antipsychotics are associated with elevated levels of the hormone, which can 
cause breast development in men.88  
Other areas that overlap with measurement-based treatment to target include 
previously mentioned lifestyle interventions, as they involve goal tracking and 
regimented follow up appointments, and annual health checks.  
 
                                                            
85 Mangurian, Niu, Schillinger, Newcomer, Dilley, and Handley, "Utilization of the Behavior Change Wheel Framework to Develop a Model to Improve 
Cardiometabolic Screening for People with Severe Mental Illness," 2. 
86 Ibid.  
87 Gray and Hardy, "Is the use of an Invitation Letter Effective in Prompting Patients with Severe Mental Illness to Attend a Primary Care Physical Health 
Check?," 348.  
88 Ibid., 353. 
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What psychiatry needs to 
change 
Regular assessment of metabolic screening rather than 
assuming this has been tackled by primary care 
Who should perform the 
behavior Psychiatrists or nurse practitioners 
When to perform the 
behavior When seeing patients that take antipsychotic drugs 
Where to perform the 
behavior At community mental health clinics 
How often to perform the 
behavior 
Annually per patient (about 10-15 times per month given a 
typical community psychiatrist’s caseload) 
For whom should they 
perform the behavior All patients taking antipsychotic drugs 
 
 
Evidence-based Care 
 
Regarding the SMI population, policy makers are uncertain of which aspects of 
health care to target for cost-containment. Recent efforts by states such as Maine and 
New Hampshire have focused on cutting antipsychotic drug costs, a component of 
care with high economic burden. However, in an effort to resolve the dilemma, 
evidence-based conclusions from many cohort studies and meta-analysis reviews 
document that it is the lack of preventive care that leads to costly outcomes, as 
adverse medical events require in-patient hospitalizations. Therefore, in order to create 
a cost impact on SMI treatment, measures to make severe mental illnesses and their 
comorbidities manageable conditions should be the primary focus. Of schizophrenia 
treatment costs, about 67% is spent on in-patient care, while pharmacotherapies 
encompass only .6%.89 Moreover, due to “financial constraints of government agencies, 
health insurance plans, and managed care companies, the investment of resources in 
high-cost residential care limits the amount of money that can be put into community 
care and pharmacotherapy.”90 This finding paints the picture that states concentrate 
their health care dollars on the cheapest antipsychotics that demonstrate efficacy, with 
no attention paid to how well patients will adhere to said drugs or how the drugs may 
affect or exacerbate the physical condition of the SMI population.  
Medicaid cost-containment parameters tailored to second-generation 
antipsychotics lead to antipsychotic nonadherence, illustrating a misallocation of state 
dollars.91 Because patients present with low adherence rates and high comorbidity 
                                                            
89 Seshamani, "Is Clozapine Cost-Effective? : Unanswered Issues," 105.  
90 Ibid.  
91 William B. Vogt, Geoffrey Joyce, Jing Xia, Riad Dirani, George Wan, and Dana P. Goldman, "Medicaid Cost Control Measures Aimed at Second- 
Generation Antipsychotics Led to Less use of all Antipsychotics," Health Affairs (Project Hope) 30, no. 12 (2011): 2346,  
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rates when doctors prescribe the cheapest medications, the up-front cost-cutting 
measures in pharmacotherapy are actually hurting state economies.  
 
Investing in better adherence for cost-containment 
 
Non-adherence to antipsychotic therapy is the primary reason for relapse and 
increased institutionalization in SMI patients. Increase in medication adherence could 
yield more than $3.28 billion in net savings.92 Although a medication adherence 
initiative projects an 18% increase in prescription drug costs, this increase will be far 
outweighed by the fruitful 68% savings from lower hospitalization rates; the rest of the 
savings will come from lower costs of outpatient care and lower rates of patient 
encounters with the criminal justice system.93  
Currently, efforts on the part of state governments and private health insurance 
plans focus on imposing prior authorization programs and other controls to stabilize drug 
spending. Prior authorization programs guide psychiatrists to prescribe lower-cost 
medications before medications that are more-costly to public payers. State 
governments have targeted second-generation antipsychotics in particular for prior 
authorization due to their high costs and usage rates among patients with Medicaid.94  
Between 1999 and 2005, annual spending per Medicaid enrollee on 
antipsychotics increased by 106%, net of inflation.95 In concurrence, prior authorization 
requirements increased dramatically during the same time frame. What states often 
overlook is the effect that such utilization management measures have imposed on 
state-funded healthcare costs. The introduction of prior authorization in Maine, for 
example, led to antipsychotic nonadherence of 29%.96 Studies in New Hampshire and 
Georgia found that implementation of prior authorization, among other restrictions, did 
reduce the use of targeted drugs, but effectively increased spending on outpatient 
and other health services. In one review, the state Medicaid programs that instituted 
prior authorization exhibited “no significant correlation between the imposition of prior 
authorization and initial levels of spending,”97 as the use of second-generation 
antipsychotics per Medicaid enrollee still rose by 14% between 1999-2008 in these prior 
authorization states.98  
The obvious deterrent for public payers to increase drug spending is the up-front 
expense of investment. Unwillingness to make this investment, however, leads to higher 
costs in the end: poor adherence is linked with poorer outcomes and higher treatment 
costs.99 Therefore, the long-term cost-effectiveness of moving towards increased drug 
spending should offer states an incentive. 
 
Better adherence using LAI antipsychotics  
 
Because non-adherence is a problem, long-acting injectable (LAI) 
antipsychotics are a treatment option that incentivizes adherence and subsequently 
lowers healthcare expenditures. LAIs offer a treatment alternative for patients with 
                                                            
92 Predmore, Mattke, and Horvitz-Lennon, "Improving Antipsychotic Adherence among Patients with Schizophrenia: Savings for States," 343-344. 
93 Ibid.  
94 Vogt, Joyce, Xia, Dirani, Wan, and Goldman, "Medicaid Cost Control Measures Aimed at Second-Generation Antipsychotics Led to Less use of all  
Antipsychotics," 2346-2347. 
95 Ibid., 2350. 
96 Ibid., 2350-2351. 
97 Ibid., 2351.  
98 Ibid., 2347-2351. 
99 Predmore, Mattke, and Horvitz-Lennon, "Improving Antipsychotic Adherence among Patients with Schizophrenia: Savings for States," 343.  
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chronic non-adherence especially.100 LAI antipsychotics do come in generic versions, 
and use of generic LAIs in place of oral antipsychotics could lead to a yearly savings of 
$1000 per patient in Medicaid programs according to a 2013 study.101 One large cohort 
study exhibited that patients who used LAI antipsychotics for more than six consecutive 
months experienced less relapses, and consequently less hospitalizations than patients 
who used LAIs for a short duration. In addition, patients who only used LAIs for a short 
duration had higher rates of comorbidity, logically contributing to more frequent 
hospitalizations and their resulting costs.102  
LAI therapy generally requires patients to receive an injection every two to six 
weeks, completely eliminating the need for oral antipsychotics, which require use one 
or more times per day.103 Psychiatrists have the option to administer certain LAI 
antipsychotics only once every three months.104 Reducing patients’ maintenance 
responsibility through such injections may offer reprieve from relapse and 
hospitalizations for sufferers of SMI. For instance, studies report that when bipolar 
disorder remains untreated due to non-adherence, the relapse rate exceeds 90% for 
manic episodes and 70% for depressive episodes. Not only have LAIs been shown to 
reduce risk of antipsychotic cessation in cohort studies, but they also can ensure a more 
stable blood level of the antipsychotic than an oral version.105 According to 
researchers, psychiatrists should target LAI antipsychotic treatment at young, recently 
diagnosed SMI patients, as they pose the highest risk of antipsychotic non-adherence 
that contributes to healthcare costs.106  
Though physicians introduced LAI antipsychotics into routine clinical practice 
decades ago, they are widely underutilized when compared to oral antipsychotics; in a 
2007 study of LAI antipsychotic use, only 10% of Medicaid insured patients used them.107 
Some authors hypothesize that the unpopularity may be due to lack of awareness of 
LAIs as a treatment option or unwillingness to increase medication costs by public 
payers.108 Negative patient attitudes towards LAIs are likely due to insufficient 
information given by physicians, suggesting that educating patients about LAI 
antipsychotics as a treatment option will increase positive patient attitudes.109  
In a survey of psychiatrists and SMI patients across Australia, Canada, and the 
United States, physicians reported preference for switching to LAIs from oral 
antipsychotics for the treatment of both adherent and non-adherent patients, even if 
efficacy would be reduced as much as 9% for the switch to once-monthly LAIs, and as 
much as 21% for the switch to LAIs lasting three months.110 As oral antipsychotic 
                                                            
100 Thomas R. Einarson, Colin Vicente, Roman Zilbershtein, Charles Piwko, Christel Bø N., Hanna Pudas, Rasmus Jensen, and Michiel E. H. Hemels,  
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101 Predmore, Mattke, and Horvitz-Lennon, "Improving Antipsychotic Adherence among Patients with Schizophrenia: Savings for States," 344.  
102 Rimal Bera, Steve Offord, Donna Zubek, Gina Lau, Jay Lin, and Craig Karson, "Hospitalization Resource Utilization and Costs among Medicaid 
Insured Patients with Schizophrenia with Different Treatment Durations of Long-Acting Injectable Antipsychotic Therapy," Journal of Clinical 
Psychopharmacology 34, no. 1 (2014): 33, 
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adherence decreased, physician preference for LAIs increased, and physicians would 
accept higher possible reductions in efficacy that could come along with the 
medication switch.111 Physicians also reported a preference for LAIs that they need only 
administer once every three months for patients with a history of skipping between 20%-
50% of doses. Patients reported preference for LAI antipsychotics for use in non-
adherent patients.112 
One particular LAI antipsychotic, ‘paliperidone palmitate’ (PP1M or PP-LAI) is a 
once-monthly second-generation LAI antipsychotic that is associated with greater 
patient adherence levels, lower polypharmacy, reduced frequency of home care 
services, and lower overall medical costs as compared to treatment with oral second-
generation antipsychotics.113 Administration dates are flexible in an effort to avoid 
missed monthly doses; physicians may administer PP-LAI 7 days before or after the 
exact monthly mark.114 In a 2014 Swedish study comparing the cost-effectiveness of 
both first and second-generation antipsychotics, PP-LAI was shown to have the lowest 
per-patient cost for institutional care, suggesting that the greater adherence that LAIs 
impose on SMI patients directly causes less institutionalizations.115 In the same study, the 
cost driver for the SMI patients sampled was institutionalization, comprising 52.5%-80.7% 
of care, depending on the antipsychotic treatment regimen.116 Although the cost-
effectiveness of the LAI ‘risperidone’ (RIS-LAI) is reasonably comparable to the cost 
effectiveness of PP-LAI, PP-LAI is paramount due to its longer duration of action, which 
allows administration to be much less frequent. With fewer administrations, missing a 
dose is less probable, which supports patient adherence.117 Switching from oral 
paliperidone palmitate to PP-LAI is easy as well – treatment with PP-LAI can safely begin 
1 day after stopping oral PP. When switching from a different LAI antipsychotic, 
physicians may administer PP-LAI in place of the next scheduled injection.118  
 
Discussion 
 
 Episodes of severe mental illness (SMI) are characterized by breaks from reality, 
among other symptoms that vary according to the diagnosis. Bipolar disorder and 
schizophrenia are the two most prevalent SMIs. Due to the severity of symptoms and 
adverse side effects from antipsychotic drug treatment, patients of this population 
often depend on the public health care system to pay for their medical care, which, 
per patient, far exceeds the healthcare expenditure as compared to that of the 
general population. 
 Antipsychotic drugs may either directly or indirectly cause metabolic disease 
and increase cardiovascular risk factors and cardiovascular related death. Because 
antipsychotic drugs are a necessary part of the treatment regimen for SMI patients, 
                                                            
Preferences from Two Randomized Long-Acting Injectable Antipsychotic Trials," Patient Preference & Adherence 10, (2016): 2131-2134,  
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114 Mahesh N. Samtani, Srihari Gopal, Cristiana Gassmann-Mayer, Larry Alphs, and Joseph M. Palumbo, "Dosing and Switching Strategies for  
Paliperidone Palmitate Based on Population Pharmacokinetic Modelling and Clinical Trial Data," CNS Drugs 25, no. 10 (2011):  
840, http://search.ebscohost.com.providence.idm.oclc.org/login.aspx?direct=true&db=a9h&AN=69849338&site=ehost-live. 
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Pharmacokinetic Modelling and Clinical Trial Data," 837. 
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psychiatrists – especially those working in community health centers – need to pay 
greater attention to the physical condition of the population in an attempt to reduce 
the high rate at which SMI sufferers experience cardiovascular morbidity. Conclusions 
from a variety of cohort studies and meta-analyses suggest that states implement a 
collaborative health care model in which psychiatrists, primary care physicians, and 
behavioral health managers (nurses) work together to holistically support the health of 
the SMI patient using lifestyle interventions, invitations for annual health checks, and 
cardiometabolic screening. These interventions will not only offer room for physical 
health improvement and better physical health maintenance, but will also save public 
payers money by reducing the encounters that SMI patients have with 
institutionalization, hospitalization, tertiary care, and the criminal justice system.  
 Because institutionalized care is the highest health cost area for the SMI 
population, an initial investment on the part of public payers to encourage psychiatrists’ 
prescribing of long-acting injectable (LAI) antipsychotics will be instrumental in 
increasing medication adherence due to the associated low maintenance regimen as 
compared to oral antipsychotic therapy. Although injectable antipsychotics will not 
directly improve cardiometabolic health, they may offer stabilization of side effects 
such as weight gain, since side effects occur the most quantitatively at the onset of 
drug therapy. When patients are not consistent with oral antipsychotic therapy, there 
are more instances of drug onset, as therapy must be restarted. Higher medication 
adherence among SMI patients will lead to less institutionalizations and effectively 
reduce the healthcare expenditure for this population. Treatment with paliperidone 
palmitate (PP-LAI) in particular offers long-term cost savings for Medicaid programs and 
other state agencies.  
SMI patients accrue a large portion of expense for public payers due to their 
mental illness, cardiometabolic comorbidities, and associated high hospitalization rates. 
However, primary care interventions and better drug therapies are available and states 
can implement them in a cost-effective manner. Doing so will not only better the 
physical health of those with severe mental illness, but will consequently relieve public 
health care programs of a substantial part of the population’s heavy health care 
burden.  
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